Clinical Trial Update: Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

Phase 3 outcome study evaluating a 75 mg dose of macitentan in patients with pulmonary arterial hypertension; status active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Macitentan (macitentan)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: ACTIVE_NOT_RECRUITING